Peptide conjugated, inosine-substituted antisense oligomer compound and method

Abstract

A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind, and (b) conjugated to the compound, an arginine-rich peptide effective to enhance the uptake of the compound into target cells. The string of bases in the compound includes at least one inosine base positioned in the string so as to limit the number of contiguous guanine bases in said string to three or fewer. The conjugate has greater cellular uptake than the compound alone, by virtue of the arginine-rich peptide, and substantially greater antisense activity greater activity than the conjugate in the absence of inosine-for guanine substitutions.

Description

[0001] This patent application claims priority to U.S. Provisional Application No. 60 / 574,048 filed on May 24, 2004, which is incorporated in its entirety herein by reference.FIELD OF THE INVENTION [0002] This invention relates to an antisense oligomer compound (i) conjugated to an arginine rich-peptide effective to enhance the uptake of the oligomer into cells, and (ii) in which strings of G bases are broken by one of more inosine bases, and methods of using such compound. REFERENCES [0003] Devi, G. R. (2002). “Prostate cancer: status of current treatments and emerging antisense-based therapies.”Curr Opin Mol Ther 4(2): 138-48. Hudziak, R. M., E. Barofsky, et al. (1996). “Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation.”Antisense Nucleic Acid Drug Dev 6(4): 267-72. [0004] Iversen, P. L. (2001). Phosphoramidite Morpholino Oligomers. Antisense Drug Technology. S. T. Crooke. New York, Marcel Dekker, Inc. Shafer, R. H. and I. Smirnov (2000). “Biological a...

AI Technical Summary

Benefits of technology

[0018] The method includes, in one aspect, an improvement in a method for enhancing the cellular uptake of a substantially uncharged oligonucleotide analog compound, by forming a conjugate of the compound and an arginine-rich peptide effective to enhance the uptake of the compound into target cells, where the compound includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind. The improvement includes substituting an inosine base for at least one guanine base in the string of bases in the compound so as to limit the number of contiguous guanine bases in the string to three or fewer, preferably two or fewer.

[0019] The improvement may be effective to enhance the water solubility of the conjugate during a purification step involving conjugate binding to and release from an cationic ion exchange resin, relative to the same conjugate in the absence of the inosine substitution. Where the target nucleic acid region includes the start codon in an mRNA, the improvement may be effective to enhance the ability of the conjugate to block translation of the protein encoded by the mRNA, relative to the same conjugate in the absence of the inosine substitution. Where the target nucleic acid region includes a donor or acceptor splice site in an preprocessed mRNA, the improvement may be effective to enhance the ability of the conjugate to mask mRNA splicing at the target region, relative to the same conjugate in the absence of the inosine substitution.

[0020] Where the target nucleic acid region includes a virally-encoded cis-acting element involved in viral replication, the improvement may be effective to enhance the ability of the conjugate to block viral replication, relative to the same conjugate in the absence of the inosine substitution.

[0030] For use in reducing the risk of coronary-artery restenosis at the site of vascular injury following an angioplasty procedure, the conjugate may be delivered by intravascular delivery, for example, via a drug-releasing stent or via intravenous injection of microbubbles carrying the drug.

Problems solved by technology

Surprisingly, it has now been found that conjugating an arginine-rich peptide to antisense compounds having runs of four or more cytosine bases, in an effort to enhance the cellular uptake of the oligomer, severely compromises the antisense activity of the compound, as well as the ability to purify the compound.

Images